Previous 10 | Next 10 |
home / stock / sphry / sphry news
Starpharma signs DEP® ADC Research Agreement with MSD PR Newswire MELBOURNE, Australia , Feb. 11, 2021 /PRNewswire/ -- Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that is has signed a Research Agreement with MSD , the tradename of Merck &am...
UK government scoops the US in authorizing the use of the Pfizer/BioNTech vaccine; roll out to commence next week. FDA and EU approval probably not far off. The Pfizer/BioNTech vaccine has first mover advantage. BioNTech stock could experience further gains at least in the short term....
Viraleze antiviral could be effective against SAS-CoV-2 and RSV. Boston Consulting Group is involved in positioning and marketing this preventative/early stage infection product. Viraleze has a fast-track to market in Europe based on antiviral activity, not efficacy of preventing COVI...
MELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Starpharma (ASX: SPL, OTCQX: SPHRY), based in Melbourne, Australia, today announced that Dr Jackie Fairley, Chief Executive Officer, will present a pre-recorded presentation at LifeSciencesInvestorForum.com on September 17 th ....
Starpharma ( OTCQX:SPHRY +8.7% ) has completed additional antiviral testing for SPL7013 against SARS‑CoV-2 in lab studies conducted at Scripps Research Institute in the U.S. More news on: Starpharma Holdings Limited, Healthcare stocks news, Read more ...
New data generated at Scripps Research Institute in the US shows that Starpharma’s antiviral nasal spray active (SPL7013) is virucidal, inactivating more than 99.9% of SARS-CoV-2, the virus that causes COVID-19 Potent antiviral activity of SPL7013 against SARS-CoV-2 was evid...
Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and ind...
DEP-coupled remdesivir (right) is soluble. Source Starpharma I’m beginning to think that Starpharma (ASX:SPL) ( SPHRY ) (SPHRF) is showing signs of overnight success after 20 years of hard slog. The company’s core expertise is in dendrimer (nanoparticle) technology, with two ...
Prospects for treating early stage COVID-19 remain uncertain, with a host of monoclonal antibody products and Starpharma’s (OTCQX: SPHRY ) nasal SPL7013 antiviral spray vying for a role for prevention of infection and early treatment. Here I update on the latest developments with remdes...
Product development activities for SPL7013, repurposed as an antiviral nasal spray, are now well advanced with formulations developed, a manufacturer selected and pilot manufacture undertaken Additional antiviral testing of SPL7013 has been completed, confirming potent antiviral act...
News, Short Squeeze, Breakout and More Instantly...
Starpharma Hldgs S/Adr Company Name:
SPHRY Stock Symbol:
OTCMKTS Market:
Uni Charm Corporation ADR (UNICY) is expected to report for Q2 2023 Clarus Therapeutics Hldgs (CRXTQ) is expected to report for quarter end 2023-06-30 Bed Bath & Beyond Inc. (BBBYQ) is expected to report for Q2 2024 CalAmp Corp. (CAMP) is expected to report $-0.04 for Q2 2024 ...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...
Verbund AG ADR (OEZVY) is expected to report for Q2 2023 Adtran Networks SE (ADVOF) is expected to report for Q2 2023 OMV AG (OMVJF) is expected to report $1.66 for Q2 2023 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 Minim Inc (MINM) is expected to r...